# Tiziana Life Sciences Shares Fall About 13% After Phase 2a Results

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/47063
Published: 2026-11-02T23:57:41.000Z
Updated: 2026-11-02T23:57:41.000Z
Section: Business

> The company said its intranasal foralumab study met both primary endpoints in patients with non-active secondary progressive multiple sclerosis.

Tiziana Life Sciences Ltd (TLSA) shares fell about 13% Monday, Nov. 2, while the company reported that its Phase 2a intranasal foralumab study met both primary endpoints in a specific multiple sclerosis patient group.

The study evaluated patients with non-active secondary progressive multiple sclerosis. Shares were down about 13% as of 3:13 p.m. ET (20:13 UTC).